Retatrutide, Tesamorelin, MOTS-c Stack for Ramadan Fat Loss

This article discusses peptides as research compounds. It is not medical advice.

The author has no financial relationship with any manufacturer, distributor, or reseller of compounds named in this article.

A stack combining retatrutide, tesamorelin, and MOTS-c is gaining attention among biohackers. The goal is amplified mitochondrial fat loss during Ramadan intermittent fasting. Each compound targets a different node in energy metabolism. Retatrutide is a triple agonist (GLP-1, GIP, glucagon). Tesamorelin is a growth hormone-releasing hormone (GHRH) analog. MOTS-c is a mitochondrial-derived peptide. Together they may shift substrate utilization toward fat while preserving lean mass.

Ramadan fasting creates a daily 12- to 16-hour dry fast. The metabolic switch to ketosis typically occurs after glycogen depletion. But some individuals struggle with energy dips and muscle loss. This stack aims to accelerate the transition and deepen mitochondrial efficiency.

Why Retatrutide Fits a Fasting Protocol

Retatrutide is still in clinical trials for obesity and type 2 diabetes. It activates GLP-1, GIP, and glucagon receptors. GLP-1 slows gastric emptying and reduces appetite. GIP improves insulin sensitivity. Glucagon promotes lipolysis and hepatic fat oxidation. During a fast, glucagon naturally rises. Retatrutide amplifies that signal.

In a phase 2 trial, retatrutide produced up to 24% body weight loss at 48 weeks. That exceeds semaglutide and tirzepatide. The glucagon component is key. It increases energy expenditure, partly through mitochondrial uncoupling. This aligns with the goals of fasting.

But retatrutide can cause gastrointestinal side effects. Nausea, vomiting, diarrhea. These may be worse on an empty stomach during Ramadan. Some users experiment with BPC-157 to improve GI tolerance with retatrutide. BPC-157 is a gastric pentadecapeptide that protects the gut lining. It may reduce nausea and accelerate healing. For a Ramadan protocol, dosing retatrutide after iftar (the evening meal) could minimize discomfort. A starting dose of 2 mg weekly is common, titrating up slowly.

Tesamorelin for Visceral Fat and GH Pulsatility

Tesamorelin is FDA-approved for HIV-associated lipodystrophy. It reduces visceral adipose tissue (VAT) by stimulating endogenous growth hormone (GH) release. GH promotes lipolysis and protein synthesis. During fasting, GH pulses increase to spare muscle. Tesamorelin can augment this natural rhythm.

Standard dosing is 2 mg subcutaneously once daily. Timing matters. Taking it before suhoor (the pre-dawn meal) may mimic the natural GH surge that occurs during sleep. Some protocols split the dose: 1 mg before suhoor and 1 mg before sleep. This maintains GH elevation throughout the fasting window.

Tesamorelin primarily targets VAT. A 26-week study showed a 15% reduction in VAT. That is significant for metabolic health. VAT is linked to insulin resistance and inflammation. During Ramadan, many people gain VAT due to large iftar meals. Tesamorelin could counteract that trend.

And it pairs well with retatrutide. Retatrutide reduces overall adiposity. Tesamorelin specifically shrinks VAT. The combination may yield a leaner body composition than either alone. Cost is a factor. Tesamorelin runs around $200 per month from research peptide suppliers. Retatrutide is pricier, often $300 or more per month. This stack is not cheap.

MOTS-c: The Mitochondrial Accelerator

MOTS-c is a 16-amino acid peptide encoded in mitochondrial DNA. It regulates metabolic flexibility. It promotes glucose uptake and fatty acid oxidation. During fasting, MOTS-c levels rise to enhance mitochondrial respiration. Supplementing exogenous MOTS-c could deepen that effect.

Research shows MOTS-c increases AMPK activation and PGC-1α expression. These are master regulators of mitochondrial biogenesis. More mitochondria mean greater fat-burning capacity. MOTS-c also improves insulin sensitivity. This is crucial during Ramadan when meal timing disrupts circadian rhythms.

Dosing typically ranges from 5 mg to 10 mg, injected subcutaneously. Frequency varies: some use it daily, others three times per week. A common protocol is 5 mg before exercise or before breaking the fast. Timing retatrutide and MOTS-c for mitochondrial fat loss is critical. Taking MOTS-c in the fasted state may maximize its effects on fatty acid oxidation. Combining it with light cardio before iftar could further boost mitochondrial adaptation.

MOTS-c is relatively affordable. A 10 mg vial costs around $48. A month's supply at 5 mg daily is about $720. Many users opt for lower doses to cut costs.

Stack Design and Ramadan-Specific Timing

The goal is to preserve muscle, burn fat, and maintain energy during the daily fast. Here is a sample protocol:

• Retatrutide: 2 mg once weekly, injected after iftar on a full stomach to reduce nausea. Titrate up by 1 mg every 4 weeks as tolerated.
• Tesamorelin: 2 mg daily, split into 1 mg at suhoor and 1 mg before bedtime. This sustains GH elevation.
• MOTS-c: 5 mg injected 30 minutes before moderate exercise, ideally in the late afternoon before iftar. On non-exercise days, inject upon waking.

Optional additions: Melanotan II is sometimes used for appetite suppression and tanning, but it can cause nausea. BPC-157 at 250 mcg twice daily may protect the gut from retatrutide side effects. KPV is an anti-inflammatory peptide that could aid recovery, but evidence is thin.

Hydration is a challenge during dry fasting. Electrolyte supplementation at suhoor and iftar is essential. Magnesium, potassium, sodium. Avoid excessive caffeine which can worsen dehydration.

Monitoring is key. Blood glucose, ketones, and body composition should be tracked. A continuous glucose monitor (CGM) can reveal how the stack affects fasting glucose. Elevated fasting glucose may indicate excessive glucagon activity from retatrutide. Adjust dosing accordingly.

Regulatory and Safety Considerations

None of these peptides are approved for general obesity or performance enhancement. Retatrutide is in phase 3 trials. Tesamorelin is approved only for HIV lipodystrophy. MOTS-c is a research chemical. Obtaining them requires navigating gray-market suppliers. Quality varies. Third-party testing is a must.

Side effects can compound. Retatrutide may cause hypoglycemia, especially when combined with fasting. Tesamorelin can lead to joint pain, insulin resistance, and carpal tunnel syndrome. MOTS-c is generally well-tolerated but long-term safety is unknown. Combining them amplifies unknown risks.

Medical supervision is advised. At minimum, regular blood work should include fasting insulin, HbA1c, liver enzymes, and IGF-1 levels. Tesamorelin will elevate IGF-1. Chronically high IGF-1 is linked to cancer risk. Cycling tesamorelin (e.g., 5 days on, 2 days off) may mitigate this.

What Practitioners Are Watching

Clinicians in the peptide space are cautiously optimistic. The synergy between a triple agonist, a GH secretagogue, and a mitochondrial peptide is theoretically sound. But real-world data is scarce. Anecdotal reports on forums describe rapid fat loss and improved energy during fasting. Some users report losing 5-8% body fat over a 4-week Ramadan cycle.

One concern is muscle loss. Fasting can be catabolic. Retatrutide's glucagon activity might worsen this. Tesamorelin's GH effect should counteract it. But the balance is delicate. Adequate protein intake at suhoor and iftar is critical. Aim for 1.6-2.2 g/kg of body weight.

Another concern is electrolyte imbalance. Dry fasting plus GLP-1-induced fluid loss can cause dehydration. Symptoms like dizziness and cramps are common. Adding electrolytes and monitoring blood pressure is prudent.

Cost remains a barrier. A full stack can exceed $1,000 per month. Some users substitute tesamorelin with ipamorelin, a cheaper GHRP. But ipamorelin has a shorter half-life and less VAT specificity. The trade-off may be worth it for budget-conscious biohackers.

Likely Trajectory

As retatrutide nears FDA approval, interest in stacking it with other peptides will grow. Tesamorelin may see expanded use in metabolic syndrome. MOTS-c research is accelerating, with trials for obesity and NAFLD. The combination could become a staple for intermittent fasting optimization.

But regulatory crackdowns on research peptides are likely. The FDA has already targeted several suppliers. Users may face supply disruptions. Compounding pharmacies might offer alternatives, but at higher costs.

In the near term, expect more anecdotal protocols to emerge. The biohacking community will refine dosing and timing. Ramadan provides a unique natural experiment. The 30-day fasting window is ideal for testing metabolic interventions. Data from CGM and DEXA scans will inform best practices.

Long-term safety studies are needed. The triple-agonist plus GH axis manipulation could have unforeseen effects on longevity. Mitochondrial overactivation might increase oxidative stress. Balancing benefits and risks will require careful iteration.

Common questions

Can I use this stack if I'm not fasting for Ramadan?

Yes, the stack is designed for any intermittent fasting protocol. The timing recommendations (retatrutide after meals, tesamorelin before fasting periods, MOTS-c before exercise) apply broadly. However, dry fasting adds unique challenges like dehydration risk. Adjust fluid and electrolyte intake accordingly.

What are the main side effects of combining retatrutide and tesamorelin?

Nausea from retatrutide is common, especially when starting. Tesamorelin can cause joint pain, swelling, and insulin resistance. Together, they may exacerbate gastrointestinal issues and blood sugar fluctuations. Monitoring glucose and titrating doses slowly can help. BPC-157 may reduce GI side effects.

How long does it take to see results from this stack?

Many users report noticeable fat loss within 2-4 weeks. Visceral fat reduction from tesamorelin may take 8-12 weeks. MOTS-c's effects on energy and endurance can be felt within days. Full mitochondrial adaptation may take months. Consistency and diet quality are major factors.

Is MOTS-c safe to use daily during a dry fast?

There are no long-term safety data for daily MOTS-c use. Short-term studies show it is well-tolerated. During dry fasting, ensure adequate hydration during non-fasting hours. MOTS-c may increase metabolic rate, raising fluid needs. Start with a lower dose (5 mg) and monitor for signs of dehydration.